Gabriele Perrone
Overview
Explore the profile of Gabriele Perrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrone G, Rigacci L, Roviello G, Landini I, Fabbri A, Iovino L, et al.
Cancer Drug Resist
. 2024 Jun;
7:21.
PMID: 38835350
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL). Despite the availability of clinical and molecular algorithms applied for the prediction of prognosis, in up to...
2.
Perrone G, Rigacci L, Urru S, Kovalchuk S, Brugia M, Fabbri A, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345090
R-CHOP standard chemotherapy is successful in about 60% of diffuse large B-cell lymphoma (DLBCL) patients. Unresponsive patients have a poor prognosis, and predictive biomarkers of response to R-CHOP are lacking....
3.
Catalano M, Roviello G, Aprile G, Ramello M, Conca R, Petrioli R, et al.
Future Oncol
. 2023 May;
19(13):937-946.
PMID: 37232154
Pancreatic cancer (PC) is one of the most lethal malignancies worldwide. This study evaluated the prognostic role of serum alanine phosphatase (ALP) and gamma-glutamyl-transferase (GGT) in metastatic PC patients. 153...
4.
Lavacchi D, Landini I, Perrone G, Roviello G, Mini E, Nobili S
Pharmacol Ther
. 2021 Jun;
229:107924.
PMID: 34175369
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma representing approximately one third of all non-Hodgkin lymphomas and about 40% of patients do not benefit of the standard first-line...
5.
Lapucci A, Perrone G, Di Paolo A, Napoli C, Landini I, Roviello G, et al.
Oncol Res
. 2020 Nov;
28(6):631-644.
PMID: 33208224
The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we...
6.
Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, et al.
Oncol Res
. 2019 Dec;
28(3):237-248.
PMID: 31806078
The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy...
7.
Mini E, Lapucci A, Perrone G, DAurizio R, Napoli C, Brugia M, et al.
Int J Cancer
. 2019 Apr;
145(9):2580-2593.
PMID: 30973654
Five-year overall survival of stage III colorectal cancer (CRC) patients treated with standard adjuvant chemotherapy (ACHT) is highly variable. Genomic biomarkers and/or transcriptomic profiles identified lack of adequate validation. Aim...
8.
Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, et al.
Oncol Res
. 2018 Mar;
26(2):333-334.
PMID: 29514732
The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are...
9.
Landini I, Lapucci A, Pratesi A, Massai L, Napoli C, Perrone G, et al.
Oncotarget
. 2017 Dec;
8(56):96062-96078.
PMID: 29221187
The anti-arthritic drug auranofin exerts also potent antitumour activity in and models, whose mechanisms are not yet well defined. From an auranofin-sensitive human ovarian cancer cell line A2780, a highly...
10.
Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, et al.
Oncol Res
. 2017 Apr;
25(9):1441-1451.
PMID: 28429680
The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are...